Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data » 11:49
05/05/21
05/05
11:49
05/05/21
11:49
IOVA

Iovance Biotherapeutics

$30.57 /

+0.395 (+1.31%)

, BMY

Bristol-Myers

$64.61 /

+0.62 (+0.97%)

Wells Fargo analyst Nick…

Wells Fargo analyst Nick Abbott noted that the results of a U.S. academic trial of Keytruda plus low-dose Yervoy in 70 melanoma patients with demonstrated resistance to a PD-(L)1 inhibitor were reported yesterday in the Journal of Clinical Oncology. While Abbott said the results "are impressive," with a response rate of 29% and median progression free and overall survival of 5 and 24.7 months, respectively, he also said he sees a "limited impact" on Iovance Biotherapeutics' (IOVA) lifileucel. Bristol-Myers (BMY) recently reported that 40% of melanoma patients receive Opdivo/Yervoy in front line treatment and his peak market share estimate for lifileucel is 20% of the "post-PD1 population," said Abbott, who has an Equal Weight rating on Iovance shares.

ShowHide Related Items >><<
IOVA Iovance Biotherapeutics
$30.57 /

+0.395 (+1.31%)

BMY Bristol-Myers
$64.61 /

+0.62 (+0.97%)

IOVA Iovance Biotherapeutics
$30.57 /

+0.395 (+1.31%)

05/03/21 Truist
Iovance Biotherapeutics initiated with a Buy at Truist
05/03/21 Truist
Iovance Biotherapeutics initiated with a Buy at Truist
04/16/21 Goldman Sachs
Iovance Biotherapeutics initiated with a Buy at Goldman Sachs
04/13/21 Cowen
Cowen starts Instil Bio at Outperform on 'second-mover advantage'
BMY Bristol-Myers
$64.61 /

+0.62 (+0.97%)

04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
IOVA Iovance Biotherapeutics
$30.57 /

+0.395 (+1.31%)

BMY Bristol-Myers
$64.61 /

+0.62 (+0.97%)

  • 29
    May
BMY Bristol-Myers
$64.61 /

+0.62 (+0.97%)

BMY Bristol-Myers
$64.61 /

+0.62 (+0.97%)

BMY Bristol-Myers
$64.61 /

+0.62 (+0.97%)

Hot Stocks
Replimune Group provides updates for CERPASS and IGNYTE trials » 07:29
05/05/21
05/05
07:29
05/05/21
07:29
REPL

Replimune Group

$32.52 /

-3.88 (-10.66%)

, REGN

Regeneron

$485.64 /

-2.64 (-0.54%)

, BMY

Bristol-Myers

$63.99 /

+0.5 (+0.79%)

Replimune Group (REPL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$32.52 /

-3.88 (-10.66%)

REGN Regeneron
$485.64 /

-2.64 (-0.54%)

BMY Bristol-Myers
$63.99 /

+0.5 (+0.79%)

REPL Replimune Group
$32.52 /

-3.88 (-10.66%)

04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
REGN Regeneron
$485.64 /

-2.64 (-0.54%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
03/24/21 Canaccord
Regeneron trial shows positive results against COVID-variants, says Canaccord
03/23/21 Piper Sandler
Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
BMY Bristol-Myers
$63.99 /

+0.5 (+0.79%)

04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
REPL Replimune Group
$32.52 /

-3.88 (-10.66%)

REGN Regeneron
$485.64 /

-2.64 (-0.54%)

BMY Bristol-Myers
$63.99 /

+0.5 (+0.79%)

  • 22
    Oct
  • 09
    Jun
  • 27
    May
REGN Regeneron
$485.64 /

-2.64 (-0.54%)

BMY Bristol-Myers
$63.99 /

+0.5 (+0.79%)

REGN Regeneron
$485.64 /

-2.64 (-0.54%)

BMY Bristol-Myers
$63.99 /

+0.5 (+0.79%)

REPL Replimune Group
$32.52 /

-3.88 (-10.66%)

REGN Regeneron
$485.64 /

-2.64 (-0.54%)

BMY Bristol-Myers
$63.99 /

+0.5 (+0.79%)

Friday
Downgrade
Fly Intel: Top five analyst downgrades » 09:56
04/30/21
04/30
09:56
04/30/21
09:56
CARR

Carrier Global

$43.35 /

-0.67 (-1.52%)

, BMY

Bristol-Myers

$62.47 /

-0.4 (-0.64%)

, STRA

Strategic Education

$77.80 /

-0.2 (-0.26%)

, CME

CME Group

$202.36 /

-1.4 (-0.69%)

, STM

STMicroelectronics

$38.10 /

-1.39 (-3.52%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Carrier Global (CARR) downgraded to Neutral from Overweight at Atlantic Equities. 2. Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying while he said the company is currently delivering "solid financial results," he has less conviction that pipeline news flow will drive shares higher given his view that TYK2 safety concerns remain an overhang and that Factor XIa risk "appears higher." 3. Strategic Education (STRA) downgraded to Neutral from Buy at BofA with analyst Gary Bisbee warning that the longer recovery path for Strayer University enrollments following pandemic declines likely pushes out a rebound in profitability until the second half of next year. 4. CME Group (CME) downgraded to Hold from Buy at Argus with analyst Kevin Heal saying the stock has risen strongly from its pandemic lows last March and surpassed his prior price target of $200. 5. STMicroelectronics (STM) downgraded to Hold from Buy at Liberum. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
STRA Strategic Education
$77.80 /

-0.2 (-0.26%)

STM STMicroelectronics
$38.10 /

-1.39 (-3.52%)

CME CME Group
$202.36 /

-1.4 (-0.69%)

CARR Carrier Global
$43.35 /

-0.67 (-1.52%)

BMY Bristol-Myers
$62.47 /

-0.4 (-0.64%)

CARR Carrier Global
$43.35 /

-0.67 (-1.52%)

04/30/21 Atlantic Equities
Carrier Global downgraded to Neutral from Overweight at Atlantic Equities
04/22/21 UBS
Carrier Global price target raised to $50 from $44 at UBS
04/19/21
Fly Intel: Top five analyst initiations
04/19/21 BofA
BofA starts Carrier Global at Buy, sees valuation gap with peers closing
BMY Bristol-Myers
$62.47 /

-0.4 (-0.64%)

04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
STRA Strategic Education
$77.80 /

-0.2 (-0.26%)

04/30/21 BofA
Strategic Education downgraded to Neutral from Buy at BofA
04/30/21 BofA
Strategic Education downgraded to Neutral from Buy at BofA
04/29/21 Barrington
Strategic Education price target lowered to $90 from $120 at Barrington
03/01/21 Barrington
Strategic Education price target lowered to $120 from $130 at Barrington
CME CME Group
$202.36 /

-1.4 (-0.69%)

04/30/21 Argus
CME Group downgraded to Hold from Buy at Argus
04/30/21 Argus
CME Group downgraded to Hold from Buy at Argus
04/29/21 Citi
CME Group price target lowered to $235 from $240 at Citi
04/20/21 Citi
CME Group price target raised to $240 from $207 at Citi
STM STMicroelectronics
$38.10 /

-1.39 (-3.52%)

04/30/21 Liberum
STMicroelectronics downgraded to Hold from Buy at Liberum
04/20/21 JPMorgan
NXP Semiconductors seen at JPMorgan as potential M&A target for Samsung
02/18/21 Berenberg
STMicroelectronics upgraded to Hold from Sell at Berenberg
01/29/21 Barclays
STMicroelectronics price target raised to EUR 42 from EUR 40 at Barclays
STRA Strategic Education
$77.80 /

-0.2 (-0.26%)

STM STMicroelectronics
$38.10 /

-1.39 (-3.52%)

CME CME Group
$202.36 /

-1.4 (-0.69%)

CARR Carrier Global
$43.35 /

-0.67 (-1.52%)

BMY Bristol-Myers
$62.47 /

-0.4 (-0.64%)

  • 06
    Aug
CME CME Group
$202.36 /

-1.4 (-0.69%)

BMY Bristol-Myers
$62.47 /

-0.4 (-0.64%)

STM STMicroelectronics
$38.10 /

-1.39 (-3.52%)

CME CME Group
$202.36 /

-1.4 (-0.69%)

BMY Bristol-Myers
$62.47 /

-0.4 (-0.64%)

STM STMicroelectronics
$38.10 /

-1.39 (-3.52%)

CARR Carrier Global
$43.35 /

-0.67 (-1.52%)

BMY Bristol-Myers
$62.47 /

-0.4 (-0.64%)

On The Fly
Bristol-Myers downgrade, Under Armour upgrade among today's top calls » 09:36
04/30/21
04/30
09:36
04/30/21
09:36
BMY

Bristol-Myers

$62.87 /

-3.17 (-4.80%)

, UAA

Under Armour

$24.41 /

+0.37 (+1.54%)

, UA

Under Armour

$20.10 /

+0.34 (+1.72%)

, NKE

Nike

$133.26 /

+2.57 (+1.97%)

, CMCSA

Comcast

$56.40 /

+2.22 (+4.10%)

, DKNG

DraftKings

$57.45 /

-2.23 (-3.74%)

, COTY

Coty

$10.18 /

-0.11 (-1.07%)

Check out today's top…

ShowHide Related Items >><<
UAA Under Armour
$24.41 /

+0.37 (+1.54%)

NKE Nike
$133.26 /

+2.57 (+1.97%)

DKNG DraftKings
$57.45 /

-2.23 (-3.74%)

COTY Coty
$10.18 /

-0.11 (-1.07%)

CMCSA Comcast
$56.40 /

+2.22 (+4.10%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
UAA Under Armour
$24.41 /

+0.37 (+1.54%)

04/30/21 Williams Capital
Under Armour upgraded to Buy on improving outlook at Williams Trading
04/30/21 Williams Capital
Under Armour upgraded to Buy from Hold at Williams Trading
04/29/21 Pivotal Research
Under Armour price target raised to $29 from $26 at Pivotal Research
04/26/21 OTR Global
Under Armour view upgraded to Positive from Mixed at OTR Global
UA Under Armour
$20.10 /

+0.34 (+1.72%)

NKE Nike
$133.26 /

+2.57 (+1.97%)

04/22/21 UBS
Nike price target lowered to $175 from $183 at UBS
04/20/21
Fly Intel: Top five analyst downgrades
04/20/21 Citi
Nike downgraded to Neutral from Buy at Citi
03/31/21 HSBC
Nike price target raised to $162 from $158 at HSBC
CMCSA Comcast
$56.40 /

+2.22 (+4.10%)

04/30/21 Oppenheimer
Comcast upgraded to Outperform from Perform at Oppenheimer
04/30/21 Oppenheimer
Comcast upgraded to Outperform from Perform at Oppenheimer
04/30/21 Pivotal Research
Comcast price target raised to $70 from $65 at Pivotal Research
04/16/21
Fly Intel: Top five analyst upgrades
DKNG DraftKings
$57.45 /

-2.23 (-3.74%)

04/30/21 Guggenheim
Guggenheim starts DraftKings with Buy on 'significant share' opportunity
04/30/21 Guggenheim
DraftKings initiated with a Buy at Guggenheim
04/26/21 Needham
DraftKings initiated with a Buy at Needham
04/07/21 Truist
Truist sees NY budget agreement's mobile sports betting deal as 'clear as mud'
COTY Coty
$10.18 /

-0.11 (-1.07%)

04/29/21 Citi
Citi adds Coty to Focus List, raises price target to $15
04/27/21 Stifel
Coty price target raised to $10 from $6 at Stifel
04/27/21 RBC Capital
Coty price target raised to $12 from $9 at RBC Capital
04/26/21 Deutsche Bank
Coty price target raised to $9 from $8 at Deutsche Bank
UAA Under Armour
$24.41 /

+0.37 (+1.54%)

NKE Nike
$133.26 /

+2.57 (+1.97%)

DKNG DraftKings
$57.45 /

-2.23 (-3.74%)

COTY Coty
$10.18 /

-0.11 (-1.07%)

CMCSA Comcast
$56.40 /

+2.22 (+4.10%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

  • 07
    Oct
  • 19
    Jun
UAA Under Armour
$24.41 /

+0.37 (+1.54%)

NKE Nike
$133.26 /

+2.57 (+1.97%)

DKNG DraftKings
$57.45 /

-2.23 (-3.74%)

COTY Coty
$10.18 /

-0.11 (-1.07%)

CMCSA Comcast
$56.40 /

+2.22 (+4.10%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

UAA Under Armour
$24.41 /

+0.37 (+1.54%)

NKE Nike
$133.26 /

+2.57 (+1.97%)

DKNG DraftKings
$57.45 /

-2.23 (-3.74%)

COTY Coty
$10.18 /

-0.11 (-1.07%)

CMCSA Comcast
$56.40 /

+2.22 (+4.10%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

UAA Under Armour
$24.41 /

+0.37 (+1.54%)

UA Under Armour
$20.10 /

+0.34 (+1.72%)

NKE Nike
$133.26 /

+2.57 (+1.97%)

DKNG DraftKings
$57.45 /

-2.23 (-3.74%)

COTY Coty
$10.18 /

-0.11 (-1.07%)

CMCSA Comcast
$56.40 /

+2.22 (+4.10%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

Hot Stocks
FDA accepts Bristol-Myers' supplemental sBLA for Opdivo » 07:03
04/30/21
04/30
07:03
04/30/21
07:03
BMY

Bristol-Myers

$62.87 /

-3.17 (-4.80%)

Bristol Myers Squibb…

Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application, or sBLA, for Opdivo, or nivolumab, for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, based on results from the CheckMate -274 trial. The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act, or PDUFA, goal date of September 3. The filing was based on results from the pivotal CheckMate -274 trial, the first positive Phase 3 trial of an immunotherapy in this setting. In the trial, Opdivo demonstrated a statistically significant and clinically meaningful increase in disease-free survival vs. placebo, regardless of patients' PD-L1 expression levels.

ShowHide Related Items >><<
BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

Downgrade
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley » 06:50
04/30/21
04/30
06:50
04/30/21
06:50
BMY

Bristol-Myers

/

+

As previously reported,…

As previously reported, Morgan Stanley analyst David Risinger downgraded Bristol-Myers to Equal Weight from Overweight with a price target of $62, down from $70. While he said the company is currently delivering "solid financial results," he has less conviction that pipeline news flow will drive shares higher given his view that TYK2 safety concerns remain an overhang and that Factor XIa risk "appears higher," Risinger tells investors. While he said he is "uninspired by the pipeline," Risinger notes that clinical trial positive, or negative, surprises can drive shares higher or lower.

ShowHide Related Items >><<
BMY Bristol-Myers
/

+

BMY Bristol-Myers
/

+

04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
BMY Bristol-Myers
/

+

BMY Bristol-Myers
/

+

BMY Bristol-Myers
/

+

BMY Bristol-Myers
/

+

Downgrade
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley » 05:29
04/30/21
04/30
05:29
04/30/21
05:29
BMY

Bristol-Myers

$62.87 /

-3.17 (-4.80%)

Morgan Stanley analyst…

Morgan Stanley analyst David Risinger downgraded Bristol-Myers to Equal Weight from Overweight with a $62 price target.

ShowHide Related Items >><<
BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

BMY Bristol-Myers
$62.87 /

-3.17 (-4.80%)

Thursday
Conference/Events
FDA Oncologic Drugs Advisory Committee to hold Virtual Meeting » 09:02
04/29/21
04/29
09:02
04/29/21
09:02
MRK

Merck

$77.12 /

-0.23 (-0.30%)

, BMY

Bristol-Myers

$66.04 /

+0.08 (+0.12%)

The Committee receives…

The Committee receives updates on Merck's Biologics License Application (BLA) 125514/S-024, trade name KEYTRUDA (pembrolizumab), for treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 ; and Merck's Biologics License Application 125514/S-042, trade name KEYTRUDA (pembrolizumab), for treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib; and Bristol-Myers Squibb's Biologics License Application (BLA) 125554/S-041, trade name OPDIVO (nivolumab), indicated as a single agent for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. The virtual meeting will be held on April 29 at 9 am. Webcast Link

ShowHide Related Items >><<
MRK Merck
$77.12 /

-0.23 (-0.30%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
MRK Merck
$77.12 /

-0.23 (-0.30%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

On The Fly
Fly Intel: Pre-market Movers » 09:00
04/29/21
04/29
09:00
04/29/21
09:00
CAT

Caterpillar

$232.60 /

+2.21 (+0.96%)

, KHC

Kraft Heinz

$40.11 /

-0.03 (-0.07%)

, HSY

Hershey

$158.93 /

+0.155 (+0.10%)

, RCL

Royal Caribbean

$87.45 /

-0.26 (-0.30%)

, TAP

Molson Coors

$51.86 /

-0.2 (-0.38%)

, BLMN

Bloomin' Brands

$28.80 /

+0.105 (+0.37%)

, AAPL

Apple

$133.80 /

-0.58 (-0.43%)

, FB

Facebook

$307.26 /

+3.755 (+1.24%)

, MRK

Merck

$77.12 /

-0.23 (-0.30%)

, TMO

Thermo Fisher

$486.20 /

-4.61 (-0.94%)

, BMY

Bristol-Myers

$66.04 /

+0.08 (+0.12%)

, IP

International Paper

$57.88 /

+0.71 (+1.24%)

, TDOC

Teladoc

$186.31 /

-3.49 (-1.84%)

, ADVM

Adverum Biotechnologies

$10.16 /

+0.29 (+2.94%)

, PLBY

PLBY Group

$49.70 /

-2.45 (-4.70%)

, PSTI

Pluristem

$4.55 /

+0.08 (+1.79%)

, MA

MasterCard

$395.79 /

+6.78 (+1.74%)

, CMCSA

Comcast

$54.14 /

-0.16 (-0.29%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

Check out this morning's…

ShowHide Related Items >><<
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

ADVM Adverum Biotechnologies
$10.16 /

+0.29 (+2.94%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

04/13/21 Deutsche Bank
Caterpillar price target raised to $259 from $232 at Deutsche Bank
04/12/21 Wolfe Research
Caterpillar initiated with an Outperform at Wolfe Research
04/01/21 Evercore ISI
Caterpillar said to be planning mid-year price increase, says Evercore ISI
03/16/21 Citi
Caterpillar price target raised to $245 from $205 at Citi
KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

04/23/21
Fly Intel: Top five analyst downgrades
04/23/21 Piper Sandler
Kraft Heinz downgraded on valuation, cost headwinds at Piper Sandler
04/22/21 Piper Sandler
Kraft Heinz downgraded to Neutral from Overweight at Piper Sandler
02/19/21 JPMorgan
Kraft Heinz downgraded to Neutral on valuation at JPMorgan
HSY Hershey
$158.93 /

+0.155 (+0.10%)

04/15/21
Fly Intel: Top five analyst upgrades
04/15/21 Goldman Sachs
Hershey upgraded to Buy from Neutral at Goldman Sachs
03/17/21
Fly Intel: Top five analyst upgrades
03/17/21 Piper Sandler
Hershey upgraded to Overweight on cost visibility at Piper Sandler
RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

04/23/21 Morgan Stanley
Royal Caribbean price target raised to $61 from $50 at Morgan Stanley
04/21/21 Berenberg
Royal Caribbean price target raised to $70 from $55 at Berenberg
04/21/21 Goldman Sachs
Royal Caribbean price target raised to $95 from $76 at Goldman Sachs
03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

04/12/21 Wolfe Research
Molson Coors initiated with a Peer Perform at Wolfe Research
03/31/21 Citi
Molson Coors price target raised to $61 from $52 at Citi
03/29/21 JPMorgan
Molson Coors price target raised to $46 from $43 at JPMorgan
03/19/21
Fly Intel: Top five analyst downgrades
BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

04/16/21 Deutsche Bank
Bloomin' Brands price target raised to $31 from $28 at Deutsche Bank
04/15/21 Wells Fargo
Bloomin' Brands price target raised to $33 from $26 at Wells Fargo
04/12/21 JPMorgan
Bloomin' Brands price target raised to $32 from $30 at JPMorgan
04/01/21 MKM Partners
Bloomin' Brands price target raised to $32 from $27 at MKM Partners
AAPL Apple
$133.80 /

-0.58 (-0.43%)

04/29/21 Canaccord
Apple price target raised to $165 from $155 at Canaccord
04/29/21 Evercore ISI
Evercore says Apple had 'trifecta' of demand, margins and monetization in Q2
04/29/21 Credit Suisse
Apple price target raised to $150 from $140 at Credit Suisse
04/29/21 Wells Fargo
Wells Fargo sees positive reaction in shares of Apple as 'justified'
FB Facebook
$307.26 /

+3.755 (+1.24%)

04/29/21 Canaccord
Facebook price target raised to $380 from $350 at Canaccord
04/29/21 Credit Suisse
Facebook price target raised to $400 from $371 at Credit Suisse
04/29/21 Jefferies
Facebook price target raised to $385 from $360 at Jefferies
04/29/21 Monness Crespi
Facebook price target raised to $460 from $375 at Monness Crespi
MRK Merck
$77.12 /

-0.23 (-0.30%)

04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

04/28/21 JPMorgan
PPD downgraded to Neutral from Overweight at JPMorgan
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
IP International Paper
$57.88 /

+0.71 (+1.24%)

04/19/21 Deutsche Bank
International Paper price target raised to $58 from $49 at Deutsche Bank
03/22/21 BMO Capital
Friday night 'big disappointment' for paperboard companies, says BMO Capital
02/05/21
Fly Intel: Top five analyst upgrades
02/05/21 Seaport Global
International Paper upgraded to Buy from Neutral at Seaport Global
TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

04/29/21 Canaccord
Teladoc price target lowered to $295 from $330 at Canaccord
04/29/21 BTIG
Teladoc price target lowered to $300 from $330 at BTIG
04/29/21 Oppenheimer
Teladoc price target lowered to $250 from $270 at Oppenheimer
04/29/21 Piper Sandler
Teladoc has 'multiple potential drivers' to estimate upside, says Piper Sandler
ADVM Adverum Biotechnologies
$10.16 /

+0.29 (+2.94%)

04/29/21 Truist
Adverum Biotechnologies downgraded to Hold from Buy at Truist
04/29/21 Truist
Adverum Biotechnologies downgraded to Hold from Buy at Truist
04/29/21 RBC Capital
Adverum Biotech cut to Sector Perform at RBC after SUSAR in ADVM-022 trial
04/29/21 RBC Capital
Adverum Biotechnologies downgraded to Sector Perform from Outperform at RBC Capital
PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

04/07/21 Roth Capital
PLBY Group price target raised to $35 from $26 at Roth Capital
04/06/21 Canaccord
Canaccord sees Nifty Gateway partnership as initial step in PLBY's NFT strategy
03/31/21 Canaccord
PLBY Group initiated with a Buy at Canaccord
03/24/21 Craig-Hallum
PLBY Group price target raised to $35 from $25 at Craig-Hallum
PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
MA MasterCard
$395.79 /

+6.78 (+1.74%)

04/28/21 Credit Suisse
Visa price target raised to $280 from $270 at Credit Suisse
04/20/21 Morgan Stanley
MasterCard price target raised to $418 from $412 at Morgan Stanley
04/20/21 Barclays
MasterCard price target raised to $402 from $380 at Barclays
04/13/21 Morgan Stanley
Synchrony loss of Gap card deal 'likely a positive,' says Morgan Stanley
CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

04/16/21
Fly Intel: Top five analyst upgrades
04/16/21 Raymond James
Comcast upgraded to Outperform from Market Perform at Raymond James
04/16/21 Raymond James
Comcast upgraded to Outperform from Market Perform at Raymond James
04/12/21 Pivotal Research
Comcast price target raised to $65 from $63 at Pivotal Research
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
09/22/20 Benchmark
Comcast price target raised to $60 from $54 at Benchmark
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

ADVM Adverum Biotechnologies
$10.16 /

+0.29 (+2.94%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

  • 01
    Mar
  • 10
    Nov
  • 14
    Oct
  • 13
    Aug
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

Hot Stocks
Bristol-Myers falls over 2% to $64.66 after Q1 earnings miss  07:06
04/29/21
04/29
07:06
04/29/21
07:06
BMY

Bristol-Myers

$66.04 /

+0.08 (+0.12%)

 
ShowHide Related Items >><<
BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.